

June 29, 2021

New Late-Breaking Data at The American Diabetes Association Show GlycoMark™ May Be an Effective Test for COVID-19 Severity

Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Atsuhiro Wakumoto; hereinafter referred to as “Nippon Kayaku”) is the manufacturer of GlycoMark™ test kits for measuring 1,5-anhydroglucitol (1,5-AG) in blood, sells test kits exclusively to Precision Diabetes, Inc. (Head Office: Raleigh, NC; President and CEO: Eric Button; hereinafter referred to as “PDI”) and supports their sales promotion activities. PDI and Patia announced today results from a study showing that the GlycoMark™ blood test may be an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients without diabetes. The data have been presented as a prestigious Late Breaking Abstract at the American Diabetes Association (ADA) 81st Scientific Sessions conference.

More information is available at https://www.prnewswire.com/news-releases/new-late-breaking-data-at-the-american-diabetes-association-show-glycomark-may-be-an-effective-test-for-covid-19-severity-301320337.html?tc=eml_cleartime.

【Reference】

About Precision Diabetes, Inc.

PDI is an emerging leader in enabling precision medicine for diabetes by using novel diabetes biomarkers and algorithms. The company’s mission is to revolutionize the diagnostic assessment of diabetes by providing a spectrum of unique diabetes tests, spanning the risk of developing diabetes to developing diabetes complications. Precision Diabetes is the exclusive supplier of the GlycoMark™ test in the U.S., Europe, Australia, the Asia-Pacific Region, the Middle East, and Mexico. More information is available at <https://www.precisiondiabetesinc.com>.

About Patia

Patia (San Sebastian, Spain) has developed a platform of solutions to assess risk, prevent and manage type 2 diabetes and gestational diabetes. Patia uniquely and cost-effectively integrates a set of high-performance genotyping tests with predictive algorithms, digital applications and lifestyle intervention. Patia's activity started by translating the knowledge of large genetic studies on diabetes performed at the Broad Institute of Harvard University and MIT (Cambridge, MA, USA). More information is available at <https://www.patiadiabetes.com>.

About GlycoMark™

The GlycoMark™ test is an FDA-cleared, for measuring 1,5-AG in serum or plasma. Nippon Kayaku sells GlycoMark™ test kits exclusively to Precision Diabetes, Inc. and provides support for their sales promotion activities.

【Please direct inquiries regarding this matter to:】

Telephone: +81- 3- 6731- 5750

IVD Dept

Specialty Chemicals, International & IVD Division

Nippon Kayaku Co., Ltd.

Mail : prir@nipponkayaku.co.jp

Telephone: +81- 3- 6731- 5237

Public Relations & Investor Relations Division

Nippon Kayaku Co., Ltd.